Iosava K V, Andriadze N A, Basadze B I, Volobuev Iu Iu, Iosava L I, Lolashvili A I
Ter Arkh. 1990;62(9):29-32.
Fifty patients with myocardial infarction (MI) were given streptodecase intravenously (the main group). Depending on the time elapsed from the appearance of the disease symptoms and the onset of streptodecase injection, the main group was distributed into 2 subgroups (less than or equal to 4 h and 4 to 8 h). The size of myocardial injury was judged from the activity CPK and ECG mapping in 35 thoracic leads. The Size of MI in the main group was significantly less than in the control group. At the same time the 2 subgroups of the patients demonstrated no significant difference in myocardial injury. This is accounted for by the fact that the majority of the patients (75%) were given the thrombolytic between the 120th and 360th minute since the disease onset. In view of the fact that streptodecase was discovered to exert a lasting beneficial effect (10 to 14 days) on hemostasis, hemorheology and microcirculation, it is suggested that the drug be used at later times of MI to prevent and treat complications consequent on microcirculatory disorders.
五十例心肌梗死(MI)患者接受了静脉注射链道酶(主要组)。根据从疾病症状出现到链道酶注射开始所经过的时间,主要组被分为两个亚组(小于或等于4小时和4至8小时)。通过35个胸导联的CPK活性和心电图映射来判断心肌损伤的大小。主要组的心肌梗死面积明显小于对照组。同时,患者的两个亚组在心肌损伤方面没有显著差异。这是因为大多数患者(75%)在疾病发作后的第120至360分钟之间接受了溶栓治疗。鉴于发现链道酶对止血、血液流变学和微循环有持久的有益作用(10至14天),建议在心肌梗死后期使用该药物来预防和治疗因微循环障碍导致的并发症。